Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
The Russian State Corporation of Nanotechnologies (Rusnano) has signed an agreement with Domain Associates, a US venture capital firm with an exclusive focus on life sciences, to establish an equally owned joint venture for the production of innovative drugs in Russia. 25 July 2011
Pharmaceutical
US drug major Bristol-Myers Squibb (NYSE: BMY) has signed a definitive agreement to acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases. 22 July 2011
Pharmaceutical
USA-based Icagen (Nasdaq: ICGN) saw its shares plunge 23% to $5.96 in premarket trading yesterday on the news that it has entered into a definitive merger agreement with global drugs behemoth Pfizer (NYSE: PFE), which already owns around 11% of the firm, targeting year-end for completion of the deal. 21 July 2011
Pharmaceutical
US drugmaker Allergan (NYSE: AGN) has entered into a definitive agreement for to acquire all of the outstanding shares and assets of the privately-held dermatology company Vicept Therapeutics, aimed at expanding its offering in this therapy segment, in which Allergan's biggest products is Botox (onabotulinumtoxin A). 21 July 2011
Pharmaceutical
The US subsidiary of Japanese drug major Shionogi (TKO: 4507) has entered into an agreement to acquire all currently marketed products from USA-based Victory Pharma, including seven treatments for pain and two for infectious diseases, including the latter's lead product Naprelan (naproxen sodium). A couple of years ago Shionogi made a $150 million offer to acquire Victory, but it did not proceed to completion due to 'unforeseen' events that occurred after the merger transaction was initiated (The Pharma Letter May 28, 2009). 19 July 2011
Pharmaceutical
Switzerland's Roche (ROG: SIX), a global leader in cancer therapeutics and diagnostics, it has signed an agreement under which it will acquire 100% of mtm laboratories AG, a privately-held company based in Heidelberg, Germany. 19 July 2011
Pharmaceutical
Acquisitive Canadian drugmaker Valeant Pharmaceuticals International (TSX: VRX) says it has signed an agreement to acquire the assets of the Ortho Dermatologics division of Janssen Pharmaceuticals, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ). Valeant's shares, which were already up 86% from the start of this year, rose a further 4.6% to $55.02 in morning trading on Friday after the announcement. 18 July 2011
Pharmaceutical
On the hunt for new therapies and new customers to drive growth, pharmaceutical executives will step up acquisition activity in the coming year, according to a recent survey by KPMG, a US audit, tax and advisory services firm, which surveyed around 100 drug industry execs in the USA. 13 July 2011
Pharmaceutical
Canada's Valeant Pharmaceuticals International (TSX: VRX) has entered into an agreement to acquire Dermik, a dermatology unit of French drug major Sanofi (Euronext: SAN)) in the USA and Canada, as well as the worldwide rights to Sculptra Aesthetic (injectable poly-L-lactic acid). 11 July 2011
Pharmaceutical
Netherlands company Qiagen (Nasdaq: QGEN) has entered into binding agreements with a group of major shareholders of Marseille, France-based Ipsogen (Alternext: ALIPS) to purchase around 61% of the firm which is focused on molecular profiling and personalized health care diagnostics for a broad range of applications in the field of hematology. The latter's board of directors has voted in favor of the deal, which is expected to complete on July 12. 10 July 2011
Pharmaceutical
Pfizer confirms it is viewing options, including sale, of its Animal Health and Nutrition businesses
Global drugs behemoth Pfizer (NYSE: PFE), which is facing patent loss on the biggest ever-selling drug, its cholesterol lowerer Lipitor (atorvastatin), yesterday announced that it is exploring strategic alternatives for its Animal Health and Nutrition businesses - with combined sales of some $5.5 billion - based on its recent, previously-announced business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. Analysts estimate that Pfizer could get more than $20 billion if it sells both businesses. 8 July 2011
Pharmaceutical
Two leading Chinese ophthalmic specialists, Shenzhen Relin Medicine and MingSight Pharmaceuticals, have set up a joint venture, Jiangsu MingSight-Relin Pharmaceutical, to develop and commercialize an innovative treatment for diabetic retinopathy in China. Financial details of the joint venture were not disclosed. 7 July 2011
Pharmaceutical
In a second acquisition in just over a year, Italian drugmaker Recordati (RC: MI) says it has signed an agreement to purchase 100% of the share capital of Dr F Frik İlac AS, a Turkish pharmaceutical company with headquarters in Istanbul. The value of the transaction (enterprise value) is around $130 million, and will be funded from existing liquidity, said Recordati. 5 July 2011
Pharmaceutical
Japan's second largest drug company, Astellas (TYO: 4503), yesterday revealed that it will sell its patent estate relating to diabetes treatments, a non-core business for the firm, to US investment fund Royalty Pharma, for $609 million, thus shedding a non-core asset acquired with its hard fought for $4 billion takeover last year of USA-based OSI Pharmaceuticals (The Pharma Letter May 17, 2010). 1 July 2011
Pharmaceutical
Cardium to acquire Transdel's Ph III topical analgesic and cosmeceutical assets for up to $4 million
Cardium Therapeutics (NYSE Amex: CXM) has entered into an agreement with fellow USA-based Transdel Pharmaceuticals (OTC Bulletin Board: TDLP) to acquire substantially all of the latter's business assets including a Phase III product candidate Ketotransdel (ketoprofen; TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain. 27 June 2011
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) said this morning that it is investing close to 1 billion Danish kroner ($192 million euros) in a new factory in Kalundborg, Denmark, for the production of biopharmaceuticals such as hemophilia medicines, growth hormone and other current and future pharmaceuticals. The factory is expected to create 120'150 new jobs in Kalundborg over the next three years. 22 June 2011
Pharmaceutical
In a move that has been previously flagged, Anglo-Swedish drug major AstraZeneca's (LSE: AZN) is near to selling its Swedish dental and health care subsidiary in a deal that could bring in a handsome $1.8 billion to the company, according to a report this morning in the UK's Financial Times. 21 June 2011
Pharmaceutical
In one of two pieces of vaccine-related news yesterday, GlaxoSmithKline (LSE: GSK) said it is acquiring the remaining 51% equity interest of Shenzhen Neptunus Interlong Bio-Technique in their joint venture company, Shenzhen GSK-Neptunus Biologicals (GSKNB), for a total cash consideration of 24 million ($39 million). After approval of this agreement by the Peoples Republic of China's authorities, GSK will become the sole owner of GSKNB. 15 June 2011
Pharmaceutical
The USA's Federal Trade Commission will require Spanish firm Grifols (GRLS: MC), a manufacturer of plasma-derived drugs, to make significant divestitures as part of a settlement allowing Grifols to acquire leading American plasma-derived drug manufacturer Talecris Biotherapeutics (Nasdaq: TLCR). 2 June 2011
Pharmaceutical
USA-based Ashland (NYSE: ASH) has agreed to acquire privately-held International Specialty Products (ISP), a global specialty chemical manufacturer of innovative functional ingredients and technologies. Under the terms of the stock purchase deal, Ashland will pay around $3.2 billion for the business in an all-cash transaction. 1 June 2011
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze